Literature DB >> 28418992

Initiation of Antiretroviral Therapy Containing Integrase Inhibitors Increases the Risk of IRIS Requiring Hospitalization.

Marine Dutertre1, Lise Cuzin, Elisa Demonchy, Pascal Puglièse, Véronique Joly, Marc-Antoine Valantin, Laurent Cotte, Thomas Huleux, Pierre Delobel, Guillaume Martin-Blondel.   

Abstract

Mesh：

Substances：

Year:  2017        PMID： 28418992     DOI： 10.1097/QAI.0000000000001397

Source DB:  PubMed          Journal:  J Acquir Immune Defic Syndr        ISSN： 1525-4135            Impact factor:   3.731


× No keyword cloud information.
  12 in total

Review 1.  Use of integrase inhibitors in HIV-associated tuberculosis in high-burden settings: implementation challenges and research gaps.

Authors:  Anushka Naidoo; Kogieleum Naidoo; Nesri Padayatchi; Kelly E Dooley
Journal:  Lancet HIV       Date:  2022-02       Impact factor: 12.767

Review 2.  Biotypes of HIV-associated neurocognitive disorders based on viral and immune pathogenesis.

Authors:  Tory P Johnson; Avindra Nath
Journal:  Curr Opin Infect Dis       Date:  2022-06-01       Impact factor: 4.968

3.  A prospective study of the immune reconstitution inflammatory syndrome (IRIS) in HIV-infected children from high prevalence countries.

Authors:  Mark F Cotton; Helena Rabie; Elisa Nemes; Hilda Mujuru; Raziya Bobat; Boniface Njau; Avy Violari; Vidya Mave; Charles Mitchell; James Oleske; Bonnie Zimmer; George Varghese; Savita Pahwa
Journal:  PLoS One       Date:  2019-07-01       Impact factor: 3.240

4.  Non-traumatic perforation of the jejunum in a human immunodeficiency virus-infected patient receiving combination antiretroviral therapy: A case report.

Authors:  Yi-Chien Lee; Chien-Chun Chiou; Jann-Tay Wang; Yi-Chun Yang; Shao-Hsien Tung; Szu-Min Hsieh
Journal:  Medicine (Baltimore)       Date:  2019-12       Impact factor: 1.889

5.  Pulmonary coinfection by Pneumocystis jirovecii and Cryptococcus species in a patient with undiagnosed advanced HIV.

Authors:  Benjamin Valente-Acosta; José Padua-Garcia; Andrés Tame-Elorduy
Journal:  BMJ Case Rep       Date:  2020-04-14

Review 6.  Addressing advanced HIV disease and mortality in global HIV programming.

Authors:  Andrew T Boyd; Ikwo Oboho; Heather Paulin; Hammad Ali; Catherine Godfrey; Anand Date; J Sean Cavanaugh
Journal:  AIDS Res Ther       Date:  2020-07-10       Impact factor: 2.250

7.  AIDS Cholangiopathy Secondary to Cytomegalovirus as Possible Unmasking Immune Reconstitution Inflammatory Syndrome in Human Immunodeficiency Virus-Infected Individual: Case Report and Review of the Literature.

Authors:  Moiz Topiwala; Nachiket Dubale; Mahender K Medisetty; Sunil Gaikwad; Divya Patel; Sanjay Pujari
Journal:  Case Rep Infect Dis       Date:  2018-07-26

Review 8.  Blocking Formation of the Stable HIV Reservoir: A New Perspective for HIV-1 Cure.

Authors:  Nilu Goonetilleke; Genevieve Clutton; Ron Swanstrom; Sarah B Joseph
Journal:  Front Immunol       Date:  2019-08-22       Impact factor: 7.561

9.  Immune reconstitution inflammatory syndrome in HIV infected late presenters starting integrase inhibitor containing antiretroviral therapy.

Authors:  Ingeborg E A Wijting; Ferdinand W N M Wit; Casper Rokx; Eliane M S Leyten; Selwyn H Lowe; Kees Brinkman; Wouter F W Bierman; Marjo E E van Kasteren; Anneloes M Postma; Vera C M Bloemen; Ghariba Bouchtoubi; Andy I M Hoepelman; Marchina E van der Ende; Peter Reiss; Bart J A Rijnders
Journal:  EClinicalMedicine       Date:  2019-12-13

10.  Antiretroviral therapy and Kaposi's sarcoma trends and outcomes among adults with HIV in Latin America.

Authors:  Jessica L Castilho; Ahra Kim; Cathy A Jenkins; Beatriz Grinsztejn; Eduardo Gotuzzo; Valeria Fink; Denis Padgett; Pablo F Belaunzaran-Zamudio; Brenda Crabtree-Ramírez; Maria Mercedes Escuder; Rosa Alencar Souza; Simone B Tenore; Sidnei R Pimentel; Maria Letícia Rodrigues Ikeda; Paulo R de Alencastro; Unai Tupinanbas; Carlos Brites; Estela Luz; Juliana Netto; Claudia P Cortes; Alexandre Grangeiro; Bryan E Shepherd; Catherine C McGowan
Journal:  J Int AIDS Soc       Date:  2021-01       Impact factor: 6.707
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.